Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

BACKGROUND: Chronic myeloid leukemia (CML) is driven by the fusion kinase Bcr-Abl. Bcr-Abl tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), revolutionized CML therapy. Nevertheless, about 20 % of CMLs display primary or acquired TKI resistance. TKI resistance can be either caused b...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Commun Signal
Autors principals: Halbach, Sebastian, Hu, Zehan, Gretzmeier, Christine, Ellermann, Julia, Wöhrle, Franziska U., Dengjel, Jörn, Brummer, Tilman
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4765141/
https://ncbi.nlm.nih.gov/pubmed/26912052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12964-016-0129-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars